Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: A protocol for systematic review and meta-analysis

被引：4
作者：
Takeuchi M. [1 ]
Kobayashi T. [1 ]
Brandão L.R. [2 ]
Ito S. [1 ]
机构：
[1] The Hospital for Sick Children, Division of Clinical Pharmacology and Toxicology, 555 University Ave, Toronto, M5G 1X8, ON
[2] The Hospital for Sick Children, Division of Pediatric Hematology/Oncology, 555 University Ave, Toronto, M5G 1X8, ON
来源：
Systematic Reviews | / 5卷 / 1期
关键词：
Children; CYP2C9; CYP4F2; Meta-analysis; Polymorphism; VKORC1; Warfarin;
D O I：
10.1186/s13643-016-0280-y
中图分类号：
学科分类号：
摘要：
Background: Despite its shortcomings, warfarin is still the most commonly prescribed anticoagulant to prevent thromboembolism in children. In adults, numerous studies confirmed the robust relationship between warfarin maintenance doses and single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9), vitamin K epoxide reductase (VKORC1), and cytochrome P450 4F2 (CYP4F2). However, their effect in children still remains to be determined. The primary objective of the present systematic review and meta-analysis is to assess the effect of genotypes of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children. Methods/design: A comprehensive literature review search using the OVID platform will be conducted by a specialized librarian, without language restrictions (i.e., MEDLINE/EMBASE/Cochrane Central Register of Controlled Trials), and all abstracts will be reviewed by two authors. Data abstraction from each eligible study will be extracted individually by two authors (MT and TK), and disagreements will be resolved through discussion with a third person (SI). Critical appraisal of the included analysis of the primary objective will follow the Newcastle-Ottawa Scale, in addition to the Strengthening the Reporting of Genetic Association study (STREGA) statement, and data reporting will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. For the meta-analysis, the presence vs. absence of each genetic polymorphism will be pursued, respectively, using a random effect model with effect size expressed as a mean difference plus 95 % confidence interval. Discussion: Our study will provide a comprehensive systematic review and meta-analysis on the potential effects of CYP2C9, VKORC1, or CYP4F2 on the warfarin maintenance dose in children, exploring the feasibility of the development of pharmacogenetic-guided warfarin dosing algorithm for children on oral vitamin K antagonists. Systematic review registration: The review has been registered with PROSPERO (registration number CRD42015016172 ). © 2016 The Author(s).
引用
收藏
相关论文
共 42 条
  • [1] Wendelboe A.M., McCumber M., Hylek E.M., Buller H., Weitz J.I., Raskob G., Global public awareness of venous thromboembolism, J Thromb Haemost, 13, 8, pp. 1365-1371, (2015)
  • [2] Raffini L., Huang Y.S., Witmer C., Feudtner C., Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007, Pediatrics, 124, 4, pp. 1001-1008, (2009)
  • [3] Streif W., Andrew M., Marzinotto V., Massicotte P., Chan A.K., Julian J.A., Mitchell L., Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients, Blood, 94, 9, pp. 3007-3014, (1999)
  • [4] Monagle P., Chalmers E., Chan A., DeVeber G., Kirkham F., Massicotte P., Michelson A.D., Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition), Chest, 133, 6, pp. 887S-968S, (2008)
  • [5] Monagle P., Newall F., Campbell J., Anticoagulation in neonates and children: pitfalls and dilemmas, Blood Rev, 24, 4-5, pp. 151-162, (2010)
  • [6] Oake N., Jennings A., Forster A.J., Fergusson D., Doucette S., Walraven C., Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis, CMAJ, 179, 3, pp. 235-244, (2008)
  • [7] Rosove M.H., Brewer P.M., Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients, Ann Intern Med, 117, 4, pp. 303-308, (1992)
  • [8] Jonas D.E., McLeod H.L., Genetic and clinical factors relating to warfarin dosing, Trends Pharmacol Sci, 30, 7, pp. 375-386, (2009)
  • [9] Kamali F., Wynne H., Pharmacogenetics of warfarin, Annu Rev Med, 61, pp. 63-75, (2010)
  • [10] Wang L., McLeod H.L., Weinshilboum R.M., Genomics and drug response, N Engl J Med, 364, 12, pp. 1144-1153, (2011)
12345